These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 24374121)
41. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Lavelle F; Bissery MC; André S; Roquet F; Riou JF Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248 [TBL] [Abstract][Full Text] [Related]
42. Chemosensitivity testing of irinotecan (CPT-11) in ovarian and endometrial carcinomas: a comparison with cisplatin. Koshiyama M; Fujii H; Kinezaki M; Ohgi S; Konishi M; Hidetaka N; Hayashi M; Yoshida M Anticancer Res; 2000; 20(3A):1353-8. PubMed ID: 10928043 [TBL] [Abstract][Full Text] [Related]
43. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity. Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251 [TBL] [Abstract][Full Text] [Related]
44. New physiologically-relevant liver tissue model based on hierarchically cocultured primary rat hepatocytes with liver endothelial cells. Xiao W; Perry G; Komori K; Sakai Y Integr Biol (Camb); 2015 Nov; 7(11):1412-22. PubMed ID: 26304784 [TBL] [Abstract][Full Text] [Related]
46. Microfluidic PDMS (polydimethylsiloxane) bioreactor for large-scale culture of hepatocytes. Leclerc E; Sakai Y; Fujii T Biotechnol Prog; 2004; 20(3):750-5. PubMed ID: 15176878 [TBL] [Abstract][Full Text] [Related]
47. Cell signaling analysis by mass spectrometry under coculture conditions on an integrated microfluidic device. Wei H; Li H; Mao S; Lin JM Anal Chem; 2011 Dec; 83(24):9306-13. PubMed ID: 22022860 [TBL] [Abstract][Full Text] [Related]
48. RECQL5 is an important determinant for camptothecin tolerance in human colorectal cancer cells. Wang X; Lu X; Zhou G; Lou H; Luo G Biosci Rep; 2011 Oct; 31(5):363-9. PubMed ID: 21210765 [TBL] [Abstract][Full Text] [Related]
49. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511 [TBL] [Abstract][Full Text] [Related]
50. Different in vitro cellular responses to tamoxifen treatment in polydimethylsiloxane-based devices compared to normal cell culture. Wang L; Yu L; Grist S; Cheung KC; Chen DDY J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Nov; 1068-1069():105-111. PubMed ID: 29073477 [TBL] [Abstract][Full Text] [Related]
51. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cao S; Rustum YM Cancer Res; 2000 Jul; 60(14):3717-21. PubMed ID: 10919639 [TBL] [Abstract][Full Text] [Related]
52. Hepatocyte growth factor (HGF), heat shock proteins (HSPs) and multidrug resistance protein (MRP) expression in co-culture of colon tumor spheroids with normal cells after incubation with interleukin-1beta (IL-1beta) and/or camptothecin (CPT-11). Paduch R; Jakubowicz-Gil J; Niedziela P Indian J Exp Biol; 2010 Apr; 48(4):354-64. PubMed ID: 20726333 [TBL] [Abstract][Full Text] [Related]
53. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. O'Leary JJ; Shapiro RL; Ren CJ; Chuang N; Cohen HW; Potmesil M Clin Cancer Res; 1999 Jan; 5(1):181-7. PubMed ID: 9918217 [TBL] [Abstract][Full Text] [Related]
54. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Chen TC; Su S; Fry D; Liebes L Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458 [TBL] [Abstract][Full Text] [Related]
55. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis. Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760 [TBL] [Abstract][Full Text] [Related]
56. Chitosan-based nanocarriers with pH and light dual response for anticancer drug delivery. Meng L; Huang W; Wang D; Huang X; Zhu X; Yan D Biomacromolecules; 2013 Aug; 14(8):2601-10. PubMed ID: 23819825 [TBL] [Abstract][Full Text] [Related]
57. Polypeptide-based Micelles for Delivery of Irinotecan: Physicochemical and In vivo Characterization. Ramasamy T; Choi JY; Cho HJ; Umadevi SK; Shin BS; Choi HG; Yong CS; Kim JO Pharm Res; 2015 Jun; 32(6):1947-56. PubMed ID: 25471199 [TBL] [Abstract][Full Text] [Related]
58. Rational design of irinotecan administration based on preclinical models. Minderman H; Cao S; Rustman YM Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):22-30. PubMed ID: 9726087 [TBL] [Abstract][Full Text] [Related]
59. Comparisons of the pharmacokinetics and the leukopenia and thrombocytopenia grade after administration of irinotecan and 5-fluorouracil in combination to rats. Umezawa T; Kiba T; Numata K; Saito T; Nakaoka M; Shintani S; Sekihara H Anticancer Res; 2000; 20(6B):4235-42. PubMed ID: 11205253 [TBL] [Abstract][Full Text] [Related]